Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Change in Accured Expenses (2022 - 2025)

Gossamer Bio (GOSS) has 4 years of Change in Accured Expenses data on record, last reported at $7.3 million in Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 4797.42% year-over-year to $7.3 million; the TTM value through Sep 2025 reached $9.3 million, up 429.14%, while the annual FY2024 figure was $1.7 million, 1853.61% up from the prior year.
  • Change in Accured Expenses reached $7.3 million in Q3 2025 per GOSS's latest filing, up from -$4.3 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $7.8 million in Q3 2023 and bottomed at -$7.8 million in Q2 2023.
  • Average Change in Accured Expenses over 4 years is $592266.7, with a median of $52000.0 recorded in 2022.
  • The widest YoY moves for Change in Accured Expenses: up 4797.42% in 2025, down 234.71% in 2025.
  • A 4-year view of Change in Accured Expenses shows it stood at -$2.5 million in 2022, then fell by 1.73% to -$2.5 million in 2023, then skyrocketed by 178.79% to $2.0 million in 2024, then skyrocketed by 265.7% to $7.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $7.3 million in Q3 2025, -$4.3 million in Q2 2025, and $4.3 million in Q1 2025.